142 results
8-K/A
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
7:18pm
to be presented at the AACR Annual Meeting – safety and efficacy data from the 40mg pharmacokinetic run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
at the AACR Annual Meeting – safety and efficacy data from the 40mg pharmacokinetic run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen Versus
8-K
ma5wah23
28 Jun 23
Atossa Therapeutics Announces $10M Stock Repurchase Program
9:01am
8-K
EX-99.1
cut74z8jmqbdec77sgne
28 Jun 23
Atossa Therapeutics Announces $10M Stock Repurchase Program
9:01am
8-K
EX-99.1
hpm 5oiwqo8w
15 May 23
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:10am
8-K
EX-99.1
akpghzwz 2epcff1x
7 Nov 22
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
EX-99.1
zpgge2
8 Aug 22
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
i8iwrumbu3sc9
6 Jun 22
Regulation FD Disclosure
2:45pm
8-K
EX-99.1
59yg5 773f
9 May 22
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
EX-99.1
s8kjapw
15 Nov 21
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
9:25am
DEFA14A
sqctymmk3xl1ucs
14 Sep 21
Additional proxy soliciting materials
4:12pm